ATE279943T1 - Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden - Google Patents
Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotidenInfo
- Publication number
- ATE279943T1 ATE279943T1 AT00902831T AT00902831T ATE279943T1 AT E279943 T1 ATE279943 T1 AT E279943T1 AT 00902831 T AT00902831 T AT 00902831T AT 00902831 T AT00902831 T AT 00902831T AT E279943 T1 ATE279943 T1 AT E279943T1
- Authority
- AT
- Austria
- Prior art keywords
- improvement
- bactericidal activity
- oligonucleotides containing
- adjuvant
- neisseria antigens
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 241000588653 Neisseria Species 0.000 title abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 239000002671 adjuvant Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12179299P | 1999-02-26 | 1999-02-26 | |
| PCT/IB2000/000176 WO2000050075A2 (en) | 1999-02-26 | 2000-02-09 | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE279943T1 true ATE279943T1 (de) | 2004-11-15 |
Family
ID=22398817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00902831T ATE279943T1 (de) | 1999-02-26 | 2000-02-09 | Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8221761B1 (https=) |
| EP (1) | EP1154790B1 (https=) |
| JP (2) | JP4812942B2 (https=) |
| AT (1) | ATE279943T1 (https=) |
| AU (1) | AU2457100A (https=) |
| CA (1) | CA2371994C (https=) |
| DE (1) | DE60015084T2 (https=) |
| ES (1) | ES2228454T3 (https=) |
| HK (1) | HK1042425B (https=) |
| PT (1) | PT1154790E (https=) |
| WO (1) | WO2000050075A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298900A1 (en) | 1996-09-17 | 2011-03-23 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
| US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| WO2000066741A2 (en) | 1999-04-30 | 2000-11-09 | Chiron S.P.A. | Conserved neisserial antigens |
| NZ515935A (en) * | 1999-05-19 | 2004-01-30 | Chiron S | Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis |
| BR0015961A (pt) | 1999-11-29 | 2003-06-10 | Chiron Spa | Antìgeno de neisseria de 85kda |
| NZ521531A (en) * | 2000-02-28 | 2005-12-23 | Chiron S | Heterologous expression of neisserial proteins |
| EP1379272B1 (en) * | 2001-04-17 | 2010-01-20 | Novartis Vaccines and Diagnostics, Inc. | Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes |
| EP1438323A4 (en) * | 2001-10-03 | 2007-08-01 | Novartis Vaccines & Diagnostic | ADJUVOUS MENINGOCOCCUS COMPOSITIONS |
| AR045702A1 (es) * | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| US7838015B2 (en) * | 2001-10-03 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Adjuvanted meningococcus compositions |
| US20050238660A1 (en) * | 2001-10-06 | 2005-10-27 | Babiuk Lorne A | Cpg formulations and related methods |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| CN107913396B (zh) | 2010-08-23 | 2022-03-08 | 惠氏有限责任公司 | 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂 |
| AU2011300409B2 (en) | 2010-09-10 | 2015-03-26 | Wyeth Llc | Non-lipidated variants of Neisseria meningitidis ORF2086 antigens |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
| MY198910A (en) | 2012-03-09 | 2023-10-02 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2021059181A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2017507C (en) * | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| DK1005368T3 (da) * | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
| US6818222B1 (en) * | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| EP1003850B1 (en) | 1997-06-06 | 2009-05-27 | The Regents of the University of California | Inhibitors of dna immunostimulatory sequence activity |
| GB9711990D0 (en) * | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| WO1999030737A1 (en) * | 1997-12-16 | 1999-06-24 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| EP1047784B2 (en) * | 1998-01-14 | 2015-03-18 | Novartis Vaccines and Diagnostics S.r.l. | Neissera meningitidis antigens |
| GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| EP2261338A3 (en) * | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| GB9810276D0 (en) * | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| GB9820003D0 (en) * | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
| GB9826886D0 (en) * | 1998-12-07 | 1999-01-27 | Smithkline Beecham Biolog | Novel compounds |
| EP1144643A1 (en) * | 1999-01-15 | 2001-10-17 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Neisseria meningitidis antigen |
| EP1149164A2 (en) * | 1999-01-22 | 2001-10-31 | SmithKline Beecham Biologics SA | Neisseria meningitidis polypeptides |
| US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| PT1187629E (pt) * | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| WO2000066741A2 (en) * | 1999-04-30 | 2000-11-09 | Chiron S.P.A. | Conserved neisserial antigens |
| GB9928196D0 (en) * | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| PT2289545T (pt) * | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Vacina de omv suplementada contra meningococos |
| US20010044416A1 (en) * | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| NZ521531A (en) * | 2000-02-28 | 2005-12-23 | Chiron S | Heterologous expression of neisserial proteins |
| US7767197B2 (en) * | 2000-06-22 | 2010-08-03 | Endo Pharmaceuticals Colorado LLC | Delivery vehicle composition and methods for delivering antigens and other drugs |
| US20040258702A1 (en) * | 2000-06-22 | 2004-12-23 | Blonder Joan P. | Vaccine delivery |
| ES2260291T3 (es) * | 2000-09-28 | 2006-11-01 | Chiron Corporation | Microparticulas para la administracion de acidos nucleicos heterologos. |
| MXPA03002643A (es) * | 2000-09-28 | 2003-06-19 | Chiron Corp | Composiciones de microparticulas y metodos para producirlas. |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| EP1379272B1 (en) * | 2001-04-17 | 2010-01-20 | Novartis Vaccines and Diagnostics, Inc. | Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes |
| US6541554B2 (en) * | 2001-05-17 | 2003-04-01 | Milliken & Company | Low-shrink polypropylene fibers |
| JP2006512401A (ja) * | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| AR045702A1 (es) * | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| US7838015B2 (en) * | 2001-10-03 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Adjuvanted meningococcus compositions |
| US6861410B1 (en) * | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
| EP2263687B1 (en) * | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| EP2172213B1 (en) * | 2003-01-30 | 2013-04-03 | Novartis AG | Injectable vaccines against multiple meningococcal serogroups |
| BRPI0410423A (pt) * | 2003-05-07 | 2006-06-06 | Sanofi Pasteur Inc | processo de imunogenicidade melhorada para vacinação meningocócica |
| US20060182793A1 (en) * | 2003-07-22 | 2006-08-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
| AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| GB0401239D0 (en) * | 2004-01-21 | 2004-02-25 | Molecularnature Ltd | Adjuvant compositions |
| GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| KR100721928B1 (ko) * | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물 |
| SI1858920T1 (sl) * | 2005-02-18 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso |
| AR054020A1 (es) * | 2005-03-23 | 2007-05-30 | Glaxosmithkline Biolog Sa | Nuevo uso |
| EA015817B1 (ru) * | 2006-10-12 | 2011-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде" |
| PE20090146A1 (es) * | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
| US20090089165A1 (en) * | 2007-09-28 | 2009-04-02 | Embarq Holdings Company, Llc | System and method for a telephony upgrade credit |
-
2000
- 2000-02-09 CA CA2371994A patent/CA2371994C/en not_active Expired - Fee Related
- 2000-02-09 HK HK02102264.3A patent/HK1042425B/en not_active IP Right Cessation
- 2000-02-09 JP JP2000600685A patent/JP4812942B2/ja not_active Expired - Fee Related
- 2000-02-09 PT PT00902831T patent/PT1154790E/pt unknown
- 2000-02-09 EP EP00902831A patent/EP1154790B1/en not_active Expired - Lifetime
- 2000-02-09 AT AT00902831T patent/ATE279943T1/de active
- 2000-02-09 AU AU24571/00A patent/AU2457100A/en not_active Abandoned
- 2000-02-09 DE DE60015084T patent/DE60015084T2/de not_active Expired - Lifetime
- 2000-02-09 US US09/914,454 patent/US8221761B1/en not_active Expired - Fee Related
- 2000-02-09 ES ES00902831T patent/ES2228454T3/es not_active Expired - Lifetime
- 2000-02-09 WO PCT/IB2000/000176 patent/WO2000050075A2/en not_active Ceased
-
2010
- 2010-05-18 JP JP2010114804A patent/JP2010174044A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000050075A3 (en) | 2001-01-11 |
| JP2010174044A (ja) | 2010-08-12 |
| HK1042425B (en) | 2005-04-01 |
| AU2457100A (en) | 2000-09-14 |
| CA2371994C (en) | 2010-09-28 |
| CA2371994A1 (en) | 2000-08-31 |
| US8221761B1 (en) | 2012-07-17 |
| DE60015084T2 (de) | 2006-02-16 |
| PT1154790E (pt) | 2005-03-31 |
| EP1154790A2 (en) | 2001-11-21 |
| JP4812942B2 (ja) | 2011-11-09 |
| JP2002537353A (ja) | 2002-11-05 |
| WO2000050075A2 (en) | 2000-08-31 |
| ES2228454T3 (es) | 2005-04-16 |
| EP1154790B1 (en) | 2004-10-20 |
| DE60015084D1 (de) | 2004-11-25 |
| HK1042425A1 (en) | 2002-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE279943T1 (de) | Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden | |
| ATE276758T1 (de) | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid | |
| NO20031646L (no) | Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol | |
| WO2001037863A3 (en) | Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen | |
| LU91778I2 (fr) | Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué. | |
| CY1112841T1 (el) | Ενεσιμα εμβολια εναντι πολλαπλων οροομαδων μηνιγγιτιδοκοκκου | |
| BR0015961A (pt) | Antìgeno de neisseria de 85kda | |
| EP1379272A4 (en) | MOLECULAR MIMETICS OF MENINGOKOKEN B EPITOPES THAT MAKE THE FORMATION OF FUNCTIONALLY EFFECTIVE ANTIBODIES | |
| EP1905449A3 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
| DE69912827D1 (de) | "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen | |
| ATE353226T1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1154790 Country of ref document: EP |
|
| EEFA | Change of the company name |